CLINICAL TRIALS PROFILE FOR INFLUENZA VACCINE, ADJUVANTED

All Clinical Trials for influenza vaccine, adjuvanted

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00133471 ↗	Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1/Phase 2	2005-03-01	The purpose of this study is to compare the body's reactions and immune responses after receiving different strengths of a H9N2 influenza virus vaccine with and without an adjuvant given into the arm muscle. Study participants will include up to 96 healthy adults, ages 18-34. The 4 dosages of the experimental H9N2 vaccine to be tested in this study are the following: 3.75, 7.5, 15, and 30-mcg (with and without MF59 adjuvant). Participants will be vaccinated on Days 0 and 28. Participants will record any vaccine side effects in a diary for 7 days following each vaccination. Participants will return to the clinic on days 2 and 7 after vaccination. Blood samples will be collected 7 days following each vaccination. Serum and nasal wash specimens will be collected before each vaccination and 4 weeks after injections (0, 4, and 8 weeks). Participants will be involved in study related procedures for up to 8 months.
NCT00296634 ↗	H5 Vaccine Alone or With Adjuvant in Healthy Adults	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1/Phase 2	2006-03-01	This randomized, controlled, double-blinded, dose-ranging, Phase I-II study in 600 healthy adults, 18 to 49 years old, is designed to investigate the safety, reactogenicity, and dose-related immunogenicity of an investigational inactivated influenza A/H5N1 virus vaccine when given alone or combined with aluminum hydroxide. A secondary goal is to guide selection of vaccine dosage levels for expanded Phase II trials based on reactogenicity and immunogenicity profiles. This dose optimization will be applied to both younger and older subject populations in subsequent studies. Subjects who meet the entry criteria for the study will be enrolled at one of 4 study sites and will be randomized into one of 8 groups to receive 2 doses of influenza A/H5N1 vaccine containing 3.75, 7.5, 15, or 45 mcg of HA with or without aluminum hydroxide adjuvant by intramuscular injection. Participants may be involved in study related procedures for up to 8 months.
NCT00912496 ↗	Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2010-06-01	This research will study safety and the body's immune (defense system) responses, including anti-H5 flu antibodies (the body's protective proteins found in the blood), to an inactivated influenza "H5" bird flu, virus vaccine. Participants will be assigned by chance to receive the vaccine injections with and without an adjuvant, (substance that can improve vaccine effectiveness so less vaccine may be used) MF59, or placebo (inactive substance). Five different vaccine dose strengths will be evaluated. About 735 healthy participants, ages 18-49 will be asked to take part in this study. Study procedures include physical exam, blood sampling, and use of a memory aid. Volunteers will participate for up to 13 months.

Clinical Trial Conditions for influenza vaccine, adjuvanted

Condition Name

Condition Name for influenza vaccine, adjuvanted
Intervention	Trials
Influenza	12
Avian Influenza	4
Immunisation	1

Condition MeSH

Condition MeSH for influenza vaccine, adjuvanted
Intervention	Trials
Influenza, Human	17
Influenza in Birds	6
Sarcoidosis	1

Clinical Trial Locations for influenza vaccine, adjuvanted

Trials by Country

Trials by Country for influenza vaccine, adjuvanted
Location	Trials
United States	41
Philippines	5
Australia	4
United Kingdom	2
New Zealand	2

Trials by US State

Trials by US State for influenza vaccine, adjuvanted
Location	Trials
Texas	6
Ohio	5
Maryland	5
Tennessee	4
Iowa	4

Clinical Trial Progress for influenza vaccine, adjuvanted

Clinical Trial Phase

Clinical Trial Phase for influenza vaccine, adjuvanted
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for influenza vaccine, adjuvanted
Clinical Trial Phase	Trials
Completed	12
Active, not recruiting	3
Not yet recruiting	1

Clinical Trial Sponsors for influenza vaccine, adjuvanted

Sponsor Name

Sponsor Name for influenza vaccine, adjuvanted
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	11
Seqirus	2
University of Oxford	1

Sponsor Type

Sponsor Type for influenza vaccine, adjuvanted
Sponsor	Trials
NIH	12
Other	9
Industry	3

Influenza vaccine, adjuvanted Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Latest Developments in Clinical Trials for the Adjuvanted Influenza Vaccine?

Recent clinical trials for adjuvanted influenza vaccines focus on enhanced immunogenicity, safety, and the ability to confer broader protection across age groups. Multiple Phase 3 trials completed or underway evaluate candidate vaccines such as an MF59-adjuvanted influenza vaccine for adults 65 and older and a protein-based adjuvanted formulation aimed at pandemics.

The key trials include:

• FOCUS Study (NCT03782221): A Phase 3 trial enrolled approximately 7,500 adults aged 65+. It compares immunogenicity and safety of MF59-adjuvanted vaccines against standard non-adjuvanted formulations, with primary endpoints of antibody response (hemagglutination inhibition titers) and adverse events monitored over 6 months.
• Vaccine Efficacy Trials (NCT04566838): Focus on high-risk populations, including elderly and immunocompromised, evaluating the vaccine's effectiveness against circulating strains in 2022-2023 flu seasons.
• Pandemic Preparedness Studies: Experimental adjuvanted protein vaccines are under trial, including efforts to assess dose-sparing and immunogenicity against emerging strains.

Preliminary data from these trials indicates higher antibody titers, improved cross-protection against drifted strains, and acceptable safety profiles consistent with previous adjuvanted vaccines.

How Does Market Size and Competition Look for the Influenza Adjuvanted Vaccine?

The global influenza vaccine market was valued at approximately $4.2 billion in 2021. The adjuvanted segment is projected to grow at a compound annual growth rate (CAGR) of around 5.8% from 2022 to 2027[1].

Major market players include:

• Seqirus: Dominates with the MF59-adjuvanted Fluad series, approved in over 50 countries for adults ≥65.
• Sanofi Pasteur: Developing adjuvanted formulations with ongoing trials to expand indications.
• GlaxoSmithKline (GSK): Focuses on pandemic and seasonal vaccines, including adjuvanted platforms.

Competitors differ primarily in adjuvant types, with MF59, AS03, and CpG-ODN being most frequently used. The development pipeline includes both reformulations of existing adjuvanted vaccines and novel platforms focusing on universal flu vaccines.

What Are the Market Drivers and Barriers for the Adjuvanted Influenza Vaccine?

Market Drivers:

• Increased efficacy in the elderly: WHO advocates for improved protection for high-risk groups.
• Pandemic preparedness: Capacity to produce dose-sparing vaccines during outbreaks.
• Surge in vaccine acceptance: Public health campaigns emphasizing stronger efficacy.

Market Barriers:

• Cost considerations: Higher prices for adjuvanted formulations compared to standard vaccines.
• Regulatory hurdles: Stringent approval processes for new adjuvants.
• Supply chain issues: Limited manufacturing capacity for adjuvants, especially during high demand.

What Is the Projection for the Influenza Adjuvanted Vaccine Market?

The market is expected to reach approximately $6.5 billion by 2027, driven primarily by new approvals, expansion into pediatric populations, and increased vaccination coverage in emerging markets[1].

Key factors influencing growth include:

• Widening indications to include children and adolescents.
• Broader acceptance of universal vaccine strategies.
• Continued investments by vaccine manufacturers in adjuvant technology.

Emerging trends highlight investments in novel adjuvants designed for improved immunogenicity and fewer side effects. The ongoing COVID-19 pandemic has increased public awareness and acceptance of adjuvanted vaccines, potentially translating into higher influenza vaccine uptake.

What Are the Key Regulatory and Policy Trends?

• Regulatory pathways: Agencies such as FDA and EMA require robust clinical data demonstrating improved efficacy and comparable safety over existing vaccines. Accelerated pathways are available under pandemic and public health emergency provisions.
• Policy shifts: Governments are prioritizing vaccination for vulnerable populations, with updated immunization guidelines increasingly favoring adjuvanted formulations.
• Funding and subsidies: Increased support from public health agencies to promote adjuvanted vaccines, especially during pandemic preparedness efforts.

What Are the Opportunities and Challenges in the Market?

Opportunities	Challenges
Development of universal flu vaccines with adjuvants	Regulatory approval complexity
Expansion into pediatric markets	Cost and reimbursement barriers
Pandemic preparedness vaccine stockpiling	Manufacturing capacity constraints

Key Takeaways

• Multiple Phase 3 clinical trials demonstrate enhanced immunogenicity and safety of adjuvanted influenza vaccines.
• The market is growing, with projections reaching approximately $6.5 billion by 2027.
• Key players include Seqirus, Sanofi, and GSK, competing in a technology-driven landscape.
• Market expansion depends on approval of broader age groups, increased vaccine acceptance, and strategic public health policies.
• The future landscape involves novel adjuvants and universal vaccine strategies, influencing both clinical development and commercialization.

FAQs

1. When are new adjuvanted influenza vaccines expected to receive regulatory approval?
Based on current clinical trial timelines, approvals are anticipated between 2023 and 2025, depending on regional regulatory agency review processes.

2. How do adjuvanted vaccines compare in cost to non-adjuvanted ones?
Adjuvanted vaccines generally cost 10-20% more, mainly due to adjuvant manufacturing and formulation complexity. Cost-effectiveness analyses are ongoing to justify higher prices in high-risk populations.

3. What are the safety concerns associated with adjuvanted influenza vaccines?
Common adverse events include injection site pain, mild fever, and fatigue. Serious adverse events are rare; thorough monitoring continues during clinical trials.

4. Which populations are most likely to benefit from adjuvanted influenza vaccines?
Elderly populations (≥65 years), immunocompromised individuals, and populations with poor responses to standard vaccines.

5. How is the adjuvanted influenza vaccine market impacted by COVID-19?
The pandemic increased demand for effective vaccines and highlighted the importance of adjuvants in pandemic preparedness, boosting investments and acceptance for adjuvanted formulations.

---

Sources:

[1] MarketResearch.com, “Global Influenza Vaccine Market Trends & Forecasts 2022-2027.”